Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.7950
-0.0100 (-1.24%)
Sep 9, 2026, 4:00 PM EDT - Market closed
Oncolytics Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.12 | 5.2 | 11.08 | 26.44 | 8.62 | 32.61 |
Short-Term Investments | - | - | - | - | 15.13 | - |
Cash & Short-Term Investments | 4.12 | 5.2 | 11.08 | 26.44 | 23.75 | 32.61 |
Cash Growth | -61.63% | -53.05% | -58.09% | 11.33% | -27.17% | 33.08% |
Other Receivables | 1.21 | 0.57 | 0.05 | 0.01 | 0.02 | 0.07 |
Receivables | 1.21 | 0.57 | 0.05 | 0.01 | 0.02 | 0.07 |
Prepaid Expenses | 1.74 | 1.07 | 1.31 | 2.46 | 1.25 | 2.19 |
Other Current Assets | - | - | - | - | 1.34 | 0.62 |
Total Current Assets | 7.07 | 6.84 | 12.44 | 28.91 | 26.37 | 35.48 |
Property, Plant & Equipment | 0.6 | 0.74 | 0.99 | 0.49 | 0.48 | 0.77 |
Other Long-Term Assets | - | - | - | - | 0.74 | - |
Total Assets | 7.67 | 7.58 | 13.42 | 29.4 | 27.58 | 36.25 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.41 | 3.5 | 0.76 | 0.82 | 1.66 | 0.47 |
Accrued Expenses | 1.68 | 2.33 | 2.57 | 1.89 | 1.03 | 1.1 |
Current Portion of Leases | 0.14 | 0.19 | 0.2 | 0.1 | 0.16 | 0.23 |
Other Current Liabilities | - | 0.08 | 1.36 | 0.4 | 0.06 | 0.32 |
Total Current Liabilities | 5.23 | 6.1 | 4.89 | 3.21 | 2.91 | 2.13 |
Long-Term Leases | 0.31 | 0.37 | 0.56 | 0.22 | 0.12 | 0.29 |
Long-Term Unearned Revenue | 4.91 | 4.91 | 4.68 | 5.1 | 4.97 | 5.32 |
Other Long-Term Liabilities | 3.39 | - | - | - | - | - |
Total Liabilities | 13.84 | 11.38 | 10.12 | 8.52 | 8 | 7.73 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | - | - | - | 326.29 | 298.53 | 309.25 |
Additional Paid-In Capital | 435.79 | 419.47 | 397.67 | 31.89 | 29.59 | 26.99 |
Retained Earnings | -448.18 | -429.5 | -400.74 | -337.72 | -309.03 | -310.88 |
Comprehensive Income & Other | 6.23 | 6.23 | 6.36 | 0.41 | 0.49 | 3.17 |
Shareholders' Equity | -6.17 | -3.8 | 3.3 | 20.87 | 19.58 | 28.53 |
Total Liabilities & Equity | 7.67 | 7.58 | 13.42 | 29.4 | 27.58 | 36.25 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.45 | 0.56 | 0.76 | 0.32 | 0.28 | 0.52 |
Net Cash (Debt) | 3.67 | 4.64 | 10.32 | 26.12 | 23.47 | 32.09 |
Net Cash Growth | -63.59% | -55.04% | -60.49% | 11.27% | -26.86% | 32.67% |
Net Cash Per Share | 0.03 | 0.05 | 0.13 | 0.39 | 0.40 | 0.60 |
Filing Date Shares Outstanding | 127.51 | 116.13 | 86.42 | 75.42 | 62.83 | 57.11 |
Total Common Shares Outstanding | 124.64 | 108.02 | 80.02 | 74.42 | 61.33 | 55.04 |
Working Capital | 1.84 | 0.74 | 7.55 | 25.7 | 23.45 | 33.36 |
Book Value Per Share | -0.05 | -0.04 | 0.04 | 0.28 | 0.32 | 0.52 |
Tangible Book Value | -6.17 | -3.8 | 3.3 | 20.87 | 19.58 | 28.53 |
Tangible Book Value Per Share | -0.05 | -0.04 | 0.04 | 0.28 | 0.32 | 0.52 |
Machinery | - | 0.62 | 0.6 | 0.56 | 0.55 | 0.54 |
Leasehold Improvements | - | 0.13 | 0.13 | 0.17 | 0.17 | 0.18 |